How Analysts Feel About Yield10 Bioscience, Inc. (YTEN) After Today’s Significant Increase?

March 14, 2018 - By Maria Brooks

The stock of Yield10 Bioscience, Inc. (NASDAQ:YTEN) is a huge mover today! The stock increased 49.43% or $0.8453 during the last trading session, reaching $2.5553. About 14.65 million shares traded or 2097.97% up from the average. Yield10 Bioscience, Inc. (NASDAQ:YTEN) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 7 months positive chart setup for the $23.23 million company. It was reported on Mar, 14 by We have $2.66 PT which if reached, will make NASDAQ:YTEN worth $929,040 more.

More notable recent Yield10 Bioscience, Inc. (NASDAQ:YTEN) news were published by: which released: “Metabolix, Inc. Announces Name Change to Yield10 Bioscience, Inc.” on January 06, 2017, also with their article: “Yield10 Bioscience Announces Fourth Quarter and Full Year 2017 Financial Results” published on March 08, 2018, published: “Yield10 Bioscience Expands Scientific Team with Two Key Hires” on February 16, 2017. More interesting news about Yield10 Bioscience, Inc. (NASDAQ:YTEN) were released by: and their article: “Yield10 Bioscience, Inc. (YTEN) Announces Results from 2017 Field Tests of …” published on January 09, 2018 as well as‘s news article titled: “UPDATE: Yield10 Bioscience, Inc. (YTEN) Climbs 200% After Granting Research …” with publication date: December 11, 2017.

Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States. The company has market cap of $23.23 million. It is developing various yield traits using proprietary advanced biotechnology trait gene discovery platforms. It currently has negative earnings. The firm was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: